10 results on '"Venugopal, B."'
Search Results
2. 893PCabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP).
3. 292P Avelumab + axitinib (A + Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial.
4. 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial.
5. LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC).
6. 1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC).
7. LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study.
8. 653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564.
9. 741P Clinical outcomes stratified by Charlson Comorbidity Index (CCI) score from a retrospective study of patients with advanced renal cell carcinoma (aRCC) who received cabozantinib as part of the UK Managed Access Program (MAP).
10. Real-world Experience of Cabozantinib in Patients with Metastatic Renal Cell Carcinoma and Cost Saving from Free-of-Cost Access Scheme.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.